4-(cyclopropylmethoxy)benzoyl chloride | 1284199-22-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(cyclopropylmethoxy)benzoyl chloride
• 英文别名: 4-(Cyclopropylmethoxy)benzoyl chloride
• CAS: 1284199-22-9
• 化学式: C₁₁H₁₁ClO₂
• 分子量: 210.66
• InChiKey: WGVIRORWENBPOV-UHFFFAOYSA-N

物化性质

• 沸点：
  325.4±15.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(cyclopropylmethoxy)benzoyl chloride 在 吡啶 、 盐酸 、 manganese(IV) oxide 、 乙醇 、 偶氮二甲酸二异丙酯 、 叠氮磷酸二苯酯 、 palladium on activated charcoal 、 potassium tert-butylate 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 、 三苯基膦 、 异丙醇 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 180.82h， 生成
  参考文献：
  名称：

  Synthesis, Structure–Activity Relationship, and Pharmacological Studies of Novel Melanin-Concentrating Hormone Receptor 1 Antagonists 3-Aminomethylquinolines: Reducing Human Ether-a-go-go-Related Gene (hERG) Associated Liabilities

  摘要：

  Recently, we discovered 3-aminomethylquinoline derivative 1, a selective, highly potent, centrally acting, and orally bioavailable human MCH receptor 1 (hMCHR1) antagonist, that inhibited food intake in F344 rats with diet-induced obesity (DIO). Subsequent investigation of 1 was discontinued because 1 showed potent hERG K+ channel inhibition in a patch-clamp study. To decrease hERG K+ channel inhibition, experiments with ligand-based drug designs based on 1 and a docking study were conducted. Replacement of the terminal p-fluorophenyl group with a cyclopropylmethoxy group, methyl group introduction on the benzylic carbon at the 3-position of the quinoline core, and employment of a [2-(acetylamino)ethyl]amino group as the amine portion eliminated hERG K+ channel inhibitory activity in a patch-clamp study, leading to the discovery of N-{3-[(1R)-1-{[2-(acetylamino)ethyl]amino}ethyl]-8-methylquinolin-7-yl}-4-(cyclopropylmethoxy)benzamide (R)-10h. The compound (R)-10h showed potent inhibitory activity against hMCHR1 and dose-dependently suppressed food intake in a 2-day study on DIO-F344 rats. Furthermore, practical chiral synthesis of (R)-10h was performed to determine the molecule's absolute configuration.

  DOI：

  10.1021/jm300167z
• 作为产物：
  描述：

  4-(环丙基-甲氧基)苯甲酸 在 氯化亚砜 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-(cyclopropylmethoxy)benzoyl chloride
  参考文献：
  名称：

  用于治疗 NASH 的一流 FABP1 抑制剂的设计、合成和生物学评价

  摘要：

  脂肪酸结合蛋白 1 (FABP1) 是一种脂肪酸转运蛋白，被认为是代谢疾病的新兴靶点。尽管有强有力的证据表明抑制 FABP1 对于改善 NASH 至关重要，但由于缺乏相关抑制剂作为药理学工具，FABP1 的药理学控制和验证受到阻碍。因此，开发有效的FABP1抑制剂是当前的研究热点。在此，我们首次报道了通过对我们内部文库进行高通量筛选而衍生的新型 FABP1 抑制剂的全面构效关系 (SAR) 研究，从而确定了最佳化合物 (IC = 4.46 ± 0.54 μM)。分子对接研究表明，与 FABP1 活性口袋周围的氨基酸形成稳定的氢键。此外，还减轻了 NASH 小鼠脂肪肝的典型组织学特征，包括脂肪变性、小叶炎症、气球样变和纤维化。此外，已被证明具有脂质代谢调节、抗氧化应激和保肝特性。这项研究可能为 NASH 领域提供有希望的见解，并为 FABP1 抑制剂的开发提供灵感。

  DOI：

  10.1016/j.ejmech.2024.116358

文献信息

• BICYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20140243310A1

  公开（公告）日：2014-08-28

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种由以下公式（I）表示的化合物：其中每个符号如规范中定义的，或其盐。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2261213A1

  公开（公告）日：2010-12-15

  The present invention provides to a compound having melanin-concentrating hormone receptor antagonistic action and low toxicity, and useful as a agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有黑色素浓集激素受体拮抗作用和低毒性的化合物，可用作预防或治疗肥胖等疾病的药剂。本发明涉及一种由下式（I）表示的化合物：其中每个符号如规范中定义的，或其盐。
• Bicyclic compound
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US09133129B2

  公开（公告）日：2015-09-15

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种由式(I)表示的化合物，其中每个符号如规范中所定义，或其盐。
• Synthesis of a stable triformylmethane synthon and its scalable application to 7-acylamino-3-formylquinoline syntheses
  作者：Yasuhiro Sawai、Masahiro Mizuno、Tatsuya Ito、Mitsuhisa Yamano

  DOI：10.1016/j.tet.2014.02.040

  日期：2014.4

  Novel 2-iminiomethylvinamidinium trihalides were isolated as stable crystals and found to be useful triformylmethane synthons with non-deliquescent nature in air. They were easier to manufacture, handle, and store than the known 2-iminiomethylvinamidinium dichloride. By virtue of in situ aminal protection, a combination of the vinamidinium salt with a secondary amine achieved an efficient and scalable synthesis of 7-acylamino-3-formylquinoline, a versatile synthetic intermediate for potent anti-obesity drugs 7-acylamino-3-aminomethy1-8-methylquinolines. (C) 2014 Elsevier Ltd. All rights reserved.
• 8-Benzamidochromen-4-one-2-carboxylic Acids: Potent and Selective Agonists for the Orphan G Protein-Coupled Receptor GPR35
  作者：Mario Funke、Dominik Thimm、Anke C. Schiedel、Christa E. Müller

  DOI：10.1021/jm400587g

  日期：2013.6.27

  8-Amido-chromen-4-one-2-carboxylic acid derivatives were identified as novel agonists at the G protein-coupled orphan receptor GPR35. They were characterized by a beta-arrestin recruitment assay and optimized to obtain agonists with nanomolar potency for the human GPR35. The compounds were found to exhibit high selectivity versus the related GPR55. The most potent agonists were 6-bromo-8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid (85, EC50 12.1 nM) and 6-bromo-8-(2-chloro-4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid (90, EC50 11.1 nM), both of which were >1700 fold selective versus GPR55. Most compounds were considerably less potent at rat and mouse than at human GPR35. 6-Bromo-8-(2-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid (87) was the only derivative that activated GPR35 of all three species at similar, low micromolar concentration. Compounds 85 and 90 are the most potent agonists at the human GPR35 known to date and might thus serve as powerful pharmacological tools to further elucidate the receptor's (patho)physiological role and its potential as a future drug target.